EUVIMEDEUVIMED entdecken
Crossref

An ACE2-Based Bimodular Fusion Protein Enables Reorientation of Endogenous Anti–Epstein-Barr Virus Antibodies Toward SARS-CoV-2 Spike

Arnaud Chêne iD, Alexandra Desrames, Alice Tomlinson, Claude Ruffié, Frédéric Tangy, Benoît Gamain

The Journal of Infectious Diseases · 2023

DOI: 10.1093/infdis/jiad329 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2023. Verfasst von Arnaud Chêne und 5 weiteren Autor:innen. Beteiligte Einrichtung: INSERM, BIGR, Université Paris Cité, and Université des Antilles. Hauptthemen laut MEDLINE: Angiotensin-Converting Enzyme 2, Antibodies, Viral, COVID-19, Herpesvirus 4, Human. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 14 Literaturangaben. Gefördert von: ERGANEO, IdEX Université Paris Cité, Institut National de la Santé et de la Recherche Médicale.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The use of soluble recombinant angiotensin-converting enzyme 2 (rACE2) as a decoy capable of blocking SARS-CoV-2 entry into cells has been envisaged as a therapeutic strategy to reduce viral loads in patients with severe COVID-19. We engineered a novel form of rACE2, fused to the Epstein-Barr virus antigen P18F3 (rACE2-P18F3), to reorient a preexisting humoral response toward Epstein-Barr virus against SARS-CoV-2 particles. Recombinant ACE2-P18F3 was able to bind to the SARS-CoV-2 spike protein, neutralize viral entry into cells, and promote the phagocytosis of spheres coated with different spike variants by monocytic cells. The results position rACE2-P18F3 as a promising therapeutic candidate to universally block coronavirus cell entry and clear viral particles.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Angiotensin-Converting Enzyme 2Antibodies, ViralCOVID-19Herpesvirus 4, HumanSpike Glycoprotein, CoronavirusHumansPeptidyl-Dipeptidase AProtein BindingRecombinant ProteinsSARS-CoV-2

Stichwörter der Autor:innen

BMFPCOVID-19Epstein-Barr virusSARS-CoV-2soluble ACE2

Substanzen

Angiotensin-Converting Enzyme 2Antibodies, ViralPeptidyl-Dipeptidase ARecombinant ProteinsSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2

Autor:innen und Institutionen

  • INSERM, BIGR, Université Paris Cité, and Université des Antilles.
  • Innovation Lab: Vaccines, Institut Pasteur, Université Paris Cité, Paris, France.

ORCID-Profile: Arnaud Chêne

Förderung

  • ERGANEO
  • IdEX Université Paris Cité
  • Institut National de la Santé et de la Recherche Médicale
  • PARAFRAP ANR-11-LABEX-0024-01

Zitieren

APA

Chêne, A., Desrames, A., Tomlinson, A., Ruffié, C., Tangy, F., & Gamain, B. (2023). An ACE2-Based Bimodular Fusion Protein Enables Reorientation of Endogenous Anti–Epstein-Barr Virus Antibodies Toward SARS-CoV-2 Spike. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiad329

Vancouver

Chêne A, Desrames A, Tomlinson A, Ruffié C, Tangy F, Gamain B. An ACE2-Based Bimodular Fusion Protein Enables Reorientation of Endogenous Anti–Epstein-Barr Virus Antibodies Toward SARS-CoV-2 Spike. The Journal of Infectious Diseases. 2023. doi:10.1093/infdis/jiad329

BibTeX
@article{Chne2023,
  author = {Chêne, Arnaud and Desrames, Alexandra and Tomlinson, Alice and Ruffié, Claude and Tangy, Frédéric and Gamain, Benoît},
  title = {An ACE2-Based Bimodular Fusion Protein Enables Reorientation of Endogenous Anti–Epstein-Barr Virus Antibodies Toward SARS-CoV-2 Spike},
  journal = {The Journal of Infectious Diseases},
  year = {2023},
  doi = {10.1093/infdis/jiad329}
}
Kostenlos starten →